Up 63% so far in 2024, the Telix Pharmaceuticals Ltd (ASX: TLX) share price isn’t going anywhere today.
Shares in the S&P/ASX 200 Index (ASX: XJO) biopharmaceutical company closed yesterday trading for $16.46 apiece. Which is where they’re likely to stay until Monday.
This morning, Telix Pharmaceuticals shares were placed on trading halt at the company’s request “pending it releasing an announcement”.
Shares are expected to remain frozen until Monday.
While the release didn’t specify, the announcement most likely will provide further details on the ASX biotech stock’s proposed initial public offering (IPO) on Wall Street.
Last Thursday, 6 June, Telix confirmed its intent to list American Depositary Shares (ADSs) on the tech-heavy Nasdaq. Each ADS will represent one ordinary share in Telix. The company is targeting US$200 million in gross proceeds from the offering.
Commenting on the Nasdaq IPO process back in late May, Telix Pharmaceuticals chair Kevin McCann said, “It enables Telix to better access the deep pool of specialist investors focused on biotechnology and radiopharmaceuticals in the US.”
As for the longer-term impact on the Telix Pharmaceuticals share price, McCann said that the increased visibility the Nasdaq listing would provide “will drive long-term value creation for shareholders”.
The post Why is the Telix Pharmaceuticals share price frozen today? appeared first on The Motley Fool Australia.
Should you invest $1,000 in Telix Pharmaceuticals right now?
Before you buy Telix Pharmaceuticals shares, consider this:
Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Telix Pharmaceuticals wasn’t one of them.
The online investing service heâs run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
And right now, Scott thinks there are 5 stocks that may be better buys…
See The 5 Stocks
*Returns as of 5 May 2024
More reading
- 4 top ASX 200 stocks to buy now for the AI revolution
- 3 ASX 300 healthcare stocks ‘well positioned to outperform’
- 2 ASX biotech shares that could be the next Telix Pharmaceuticals
- Telix Pharmaceuticals share price jumps to record high on Nasdaq IPO launch
- 3 high-flying ASX shares that could keep on climbing
Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Telix Pharmaceuticals. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
Leave a Reply